- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rxsight Inc (RXST)
Rxsight Inc stock price live, this page displays NASDAQ RXST stock exchange data. View the RXST premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rxsight Inc real time stock price chart below.
What Is the Rxsight Inc Stock Price Today?
The Rxsight Inc stock price today is 11.46.
What Is the Stock Symbol for Rxsight Inc?
The stock symbol for Rxsight Inc is "RXST."
What Stock Exchange Does Rxsight Inc Trade On?
Rxsight Inc is listed and trades on the NASDAQ stock exchange.
Is Rxsight Inc a Good Stock to Buy?
Determining whether Rxsight Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXST quote. (ISIN: US78349D1072)
What Is the Rxsight Inc Stock Price Today?
The Rxsight Inc stock price today is 11.46.
What Is the Stock Symbol for Rxsight Inc?
The stock symbol for Rxsight Inc is "RXST."
What Stock Exchange Does Rxsight Inc Trade On?
Rxsight Inc is listed and trades on the NASDAQ stock exchange.
Is Rxsight Inc a Good Stock to Buy?
Determining whether Rxsight Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXST quote. (ISIN: US78349D1072)
NASDAQ
Currency in USD
11.46
+0.45(+4.09%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.91
11.59
52 wk Range
6.32
37.13
RXST is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.9111.59
52 wk Range
6.3237.13
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RXST Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
10.33
Downside
-9.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Rxsight Inc For: 23 December
- Investing.com
- Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 8K Rxsight Inc For: 23 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Rxsight Inc Company Profile
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Rxsight Inc Earnings Call Summary for Q3/2025
- RxSight reported Q3 2025 revenue of $30.3M, exceeding forecasts by 19.86%, while EPS loss narrowed to $0.04 versus expected $0.38, despite stock declining 7.33% in aftermarket trading.
- Gross margin improved significantly to 79.9%, up 844 basis points year-over-year, despite a 14% YoY revenue decrease, reflecting effective cost management strategies.
- The company is strategically shifting focus toward expanding Light Adjustable Lens (LAL) procedures and international presence, with LAL segment growing 6% year-over-year.
- Management provided full-year 2025 revenue guidance of $125-130M with gross margin of 76-77%, projecting sequential growth in 2026 despite challenges from declining cataract surgery reimbursement rates.
Last Updated: 11/06/2025, 06:36 AM
Read Full TranscriptCompare RXST to Peers and Sector
Metrics to compare | RXST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRXSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.7x | −3.2x | −0.6x | |
PEG Ratio | 1.55 | −0.17 | 0.00 | |
Price/Book | 1.8x | 4.0x | 2.6x | |
Price / LTM Sales | 3.5x | 3.7x | 3.2x | |
Upside (Analyst Target) | −9.2% | 26.7% | 41.8% | |
Fair Value Upside | Unlock | 5.8% | 5.1% | Unlock |
Analyst Ratings
1 Buy
7 Hold
2 Sell
Ratings:
10 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 10.33
(-9.83% Downside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-0.04 / -0.38
Revenue / Forecast
30.30M / 25.28M
People Also Watch
FAQ
What Is the Rxsight (RXST) Stock Price Today?
The Rxsight stock price today is 11.46
What Stock Exchange Does Rxsight Trade On?
Rxsight is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Rxsight?
The stock symbol for Rxsight is "RXST."
What Is the Rxsight Market Cap?
As of today, Rxsight market cap is 471.61M.
What Is Rxsight's Earnings Per Share (TTM)?
The Rxsight EPS (TTM) is -0.88.
When Is the Next Rxsight Earnings Date?
Rxsight will release its next earnings report on Mar 09, 2026.
From a Technical Analysis Perspective, Is RXST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Rxsight Stock Split?
Rxsight has split 0 times.
How Many Employees Does Rxsight Have?
Rxsight has 498 employees.
What is the current trading status of Rxsight (RXST)?
As of Dec 24, 2025, Rxsight (RXST) is trading at a price of 11.46, with a previous close of 11.01. The stock has fluctuated within a day range of 10.91 to 11.59, while its 52-week range spans from 6.32 to 37.13.
What Is Rxsight (RXST) Price Target According to Analysts?
The average 12-month price target for Rxsight is USD10.33333, with a high estimate of USD14 and a low estimate of USD8. 1 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an -9.83% Downside potential.
What Is the RXST Premarket Price?
RXST's last pre-market stock price is 11.03. The pre-market share volume is 1,240.00, and the stock has decreased by 0.02, or 0.18%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.